The causal role of high-density lipoprotein (HDL) cholesterol in cardioprotection has been questioned by genetic and randomized studies. Novel measures that relate to HDL function may contribute new information to the prediction of cardiovascular risk. Apolipoprotein C-III (apoC-III) is a key regulator of lipoprotein metabolism. We investigated whether subspecies of HDL defined by apoC-III are associated with coronary heart disease (CHD).
H
igh-density lipoprotein (HDL) cholesterol is a strong, inverse predictor of coronary heart disease (CHD). 1 However, the potential causal role of HDL cholesterol in cardioprotection has been called into question by randomized studies of potent HDL cholesterol-raising drugs that failed to lower CHD rates. [2] [3] [4] Genetic observational studies that do not find fewer cardiovascular events among individuals with genetically determined high HDL cholesterol levels further highlight the limitations in using HDL cholesterol to evaluate novel therapeutics aimed at CHD reduction. 5, 6 Emerging measures of key antiatherogenic properties of HDL, such as its capacity to mediate cholesterol efflux from macrophages, are not captured by average HDL cholesterol levels. 7, 8 The strong inverse association between cholesterol efflux capacity and cardiovascular events suggests that markers reflecting functional properties of HDL, rather than its cholesterol concentration alone, may substantially contribute to our understanding of HDL's role in atherosclerosis.
The heterogeneous protein composition of HDL led to the proposal that HDL circulates in subtypes based on the presence and absence of certain apolipoproteins that guide their downstream metabolism and function by mediating their interactions with enzymes and receptors. 9 Growing evidence suggests that apolipoprotein C (apoC) -III, a small apolipoprotein present on some but not all very low-density lipoprotein (LDL), LDL, and HDL particles may play a key role in lipid metabolism. [10] [11] [12] Rare mutations in the APOC3 gene that lower circulating apoC-III levels also associate with lower triglycerides and a greatly reduced risk of cardiovascular disease. 13, 14 ApoC-III inhibits hepatic clearance of apoBcontaining lipoproteins from the circulation by blocking the interaction of apoE and apoB100 with hepatic receptors, and in large amounts it can inhibit lipases that metabolize the triglyceride in these lipoproteins. 12, 15, 16 It is not known whether apoC-III affects HDL metabolism. However, apoC-III diminishes the protective functions of HDL that are unrelated to lipoprotein metabolism, such as inhibition of monocyte adhesion to endothelial cells, an early event in atherosclerosis. 17 In US male health professionals and female nurses, we found that the cholesterol concentrations of HDL defined by the presence or absence of apoC-III have opposite associations with CHD. 18 However, this relatively small study was not powered to investigate potential susceptible subgroups and did not include measures of apoA-I, the main structural protein of HDL that is strongly associated with the risk of CHD.
To investigate whether subspecies of HDL apoA-I containing or lacking apoC-III are associated with incident CHD, we prospectively studied this in 2 large population-based studies with greater racial and ethnic diversity and a large number of well-defined incident events. We further meta-analyzed all current data on HDL subspecies according to apoC-III, totaling >2900 incident events, and queried for potential effect modification by important cardiovascular risk factors, including obesity, smoking, and clinical HDL cholesterol measures.
METHODS
The data, analytic methods, and study materials will be made available to other researchers for purposes of reproducing the results only with proper Institutional Review Board approvals and strict adherence to cohort-specific regulations. Requests for data can be directed to senior authors (R.L.M., K.O., and E.B.R.).
Study Populations and Clinical End Points
Between 2000 and 2002, MESA (Multi-Ethnic Study of Atherosclerosis) enrolled 6814 men and women 45 to 84 years of age from 6 regions in the United States who self-identified as primarily of white, Chinese, black, or Hispanic descent and were free of clinical CVD. 19 Information on demographics, anthropometrics, and medications were obtained at baseline through questionnaires and physical examinations. Incident CHD events (myocardial infarction, resuscitated cardiac arrest, and CHD death) were ascertained and adjudicated as previously reported. 20 By the end of follow-up in December 2013, 300 incident CHD events had occurred.
The DCH study (Danish Diet, Cancer, and Health) is a population-based study started in 1993 to 1997 when 57 053 Danish-born residents, 50 to 65 years of age and free of cancer, participated in a clinical examination and detailed lifestyle survey. 21 All incident CHD events occurring between baseline and May 2008 (myocardial infarction, resuscitated cardiac arrest, and fatal CHD) were included by linking
Clinical Perspective
What Is New?
• We identified a subspecies of high-density lipoprotein (HDL) that contains apolipoprotein C (apoC)-III. HDL containing apoC-III comprises 5% to 6% of apoA-I or 10% to 15% of HDL cholesterol.
• In 4 prospective studies, HDL containing apoC-III was associated with a greater risk of coronary heart disease, whereas HDL that lacked apoC-III was inversely associated with risk and more strongly than the total HDL.
What Are the Clinical Implications?
• ApoC-III may adversely affect antiatherogenic properties of HDL.
• HDL containing apoC-III may be useful to evaluate responses to future HDL-raising therapies.
• Measures that reflect the function or structure of HDL may provide information on cardiovascular risk beyond traditional HDL concentrations.
Study Designs and Laboratory Measurements
Blood was sampled at the baseline study visit in both studies and stored at −70°C in MESA and -150°C in DCH. Our lipid laboratory at the Harvard T.H. Chan School of Public Health received plasma from all MESA participants except 1000 participants excluded by the study steering committee because of extensive laboratory testing on baseline samples, leading to the depletion of stored plasma in these randomly chosen individuals (n=5796). In the DCH study, a case cohort was designed for the assessment of blood markers. 25 Plasma samples were received from all incident CHD cases and a subcohort of randomly sampled participants drawn from the study population who were free of CHD at baseline (n=1824).
HDL subspecies according to apoC-III were assessed by concentrations of apoA-I with and without apoC-III in both studies. In MESA, a modified sandwich ELISA first fractionates plasma by binding lipoproteins containing apoC-III using affinity-purified antihuman apoC-III and subsequently quantifies the concentration of apoA-I in the apoC-III-bound and unbound fractions by standard ELISA assays. Also, the concentration of total plasma apoC-III was measured by ELISA separately. On exclusion of 45 participants with implausible apolipoprotein ranges, 27 with missing information on CHD events, and 67 with missing covariate data, 5657 MESA participants remained for our analyses.
In the assessment of DCH samples, we used immunoaffinity chromatography with anti-apoC-III antibody to separate the plasma into fractions with and without apoC-III. Subsequently, concentrations of apoA-I in the apoC-III-bound and unbound fractions were assessed by standard ELISA. To compare with our earlier report where HDL was quantified using measures of HDL cholesterol concentrations rather than apoA-I concentrations, 18 we also assessed the concentrations of cholesterol (in HDL) containing and lacking apoC-III upon precipation of the apoB-containing lipoproteins. Total plasma levels of triglycerides, apoB, apoC-III, and apoC-III in the HDL fraction were also assessed in our lipid laboratory. From the original 3830 participants in the DCH case cohort, 161 did not have enough samples left for qualitative analyses in the lipid laboratory. We also excluded 27 samples that did not pass quality control, and therefore the final case-cohort set included 1949 incident CHD cases and 1693 noncases. Because of the case-cohort design, 57 incident CHD cases also belonged to the reference subcohort (n=1750). More details on laboratory methodology are available in the onlineonly Data Supplement.
Additional Cohorts for Meta-Analysis
To provide the most robust estimate of risk, we considered all available studies of incident CHD that incorporated the measures of HDL subspecies according to apoC-III content and conducted a cumulative meta-analysis. The inclusion of our previous investigations of HDL cholesterol containing and lacking apoC-III in case-control studies nested within the NHS (Nurses' Health Study) and the HPFS (Health Professionals Follow-Up Study) (details in the online-only Data Supplement) 18 summed to 2997 incident CHD events. In a subset of the HPFS controls (n=301), cholesterol efflux from macrophages was also measured using methods previously described. 8 
Statistical Analyses
We assessed characteristics of the MESA participants and the random subcohort of the DCH using means (medians of skewed variables) and proportions of covariates of interest.
In both MESA and DCH, the risk of incident CHD was analyzed using Cox proportional hazards regression, where participants contributed person time from baseline until the date of an event, death, or end of follow-up, whichever occurred first. In the DCH, Kalbfleisch and Lawless weights and robust variance suitable for the case-cohort data were applied. 26 All analyses adjusted for age and sex; multivariable-adjusted models also included all traditional atherosclerotic cardiovascular disease risk factors except for HDL cholesterol. Thus, prevalent diabetes mellitus, treatment with antihypertensive medication, race/ethnicity (MESA only), systolic blood pressure, smoking, and total cholesterol were included in multivariable models. 27 The 2 subfractions of HDL apoA-I were simultaneously included in all analyses of these subspecies because they sum to a total HDL apoA-I. In each study, we assessed the heterogeneity between the 2 associations of HDL containing and lacking apoC-III with the risk of CHD in Cox regression models with both subfractions included as linear terms per study-specific SDs as well as per 5 mg/dL. We then tested the linear hypothesis that the regression coefficients for the 2 subfractions were equal (using a 1 df Wald test).
Initial evaluations found no statistically significant difference in associations of HDL subspecies with risk of CHD across sex and race/ethnicity (MESA only), and therefore results from the total study population are presented. No evidence for nonproportionality of hazards was found by examining martingale residuals. A subsequent model additionally included log-transformed plasma triglycerides and LDL cholesterol (available in MESA) or total apoB (available in DCH) concentrations to address whether the associations were independent of adjustment for these clinical risk factors.
The results based on the NHS/HPFS data were used as previously reported (also available in the online-only Data Supplement), 18 and with the additional measures of cholesterol efflux in a subset of HPFS controls, we estimated the age-adjusted Spearman rank correlations with the apoC-IIIbased HDL subspecies.
Meta-Analysis
To test relationships with CHD across the diverse measures and study designs, we performed meta-analyses per studyspecific SDs, quintiles, and per 5 mg/dL fixed increment of the HDL measures containing or lacking apoC-III. In the absence of between-study heterogeneity, we estimated the fixed effects. 28 We also pooled all estimates from cohort-specific ORIGINAL RESEARCH ARTICLE analyses of HDL subspecies with risk of CHD in strata of CVD risk factors: sex, obesity, smoking, diabetes mellitus, use of cholesterol-lowering medication, and clinically defined low HDL cholesterol (HDL cholesterol <40 mg/dL). 29 Statistical analyses were performed using SAS 9.4 (SAS Institute) and STATA 11 (STATA Corp).
The first author had full access to all of the data in the study and takes responsibility for the integrity of the data and accuracy of the data analysis. Written informed consent was obtained from all participants, and the protocol was approved by the Institutional Review Board at the Harvard T.H. Chan School of Public Health, all MESA study sites, the Danish National Committee on Health Research Ethics, and the Danish Data Protection Agency.
RESULTS
The mean age at study entry was 63 years in MESA and 57 years in DCH. In MESA, 52% were female, and 37% self-identified as white, 12% as Chinese, 29% as black, and 22% as Hispanic, whereas DCH participants were Danish-born residents (Table 1) . At baseline, 17% of MESA participants reported use of lipid-lowering medication, whereas this practice was uncommon in Denmark (<1% reported use). Similarly, despite higher average systolic blood pressure in Danes, fewer reported a physician diagnosis of hypertension, and taking medicine for this condition was uncommon. The median apoA-I levels were 125 mg/dL in MESA and 136 mg/dL in DCH, and on average 6% to 8% of the HDL apoA-I contained apoC-III.
The age-adjusted Spearman rank correlation (in a subset of the HPFS participants) between cholesterol efflux and proportion of HDL cholesterol that has apoC-III was 0.12 (P=0.2). Age-and sex-adjusted Spearman rank correlations of the HDL subspecies with each other (0.7, P<0.01) and with triglycerides and total apoC-III in Table I in the online-only Data Supplement were based on the MESA cohort. Although total apoC-III was moderately correlated with triglycerides (0.6, P<0.01), the HDL subspecies containing or lacking apoC-III were weakly or not correlated with triglycerides.
Associations With Risk of Coronary Heart Disease in MESA and DCH
The concentration of total HDL apoA-I was inversely associated with the risk of CHD in both cohorts (Table 2) . However, the 2 HDL subspecies defined by the presence versus absence of apoC-III were differentially associated with the risk of CHD. Only HDL apoA-I lacking apoC-III was inversely associated with the risk of CHD (MESA: hazard ratio per SD, 0.83; 95% confidence interval [CI], 0.71-0.96; DCH: hazard ratio, 0.75; 95% CI, 0.66-0.84), whereas the risk associated with each SD increment in HDL apoA-I containing apoC-III was 1.09 (95% In DCH, hypertension, diabetes mellitus, and hypercholesterolemia were self-reported physician diagnoses. Apo indicates apolipoprotein; ApoC-III, apolipoprotein C-III; ApoA-I, apolipoprotein A-I; DCH, Danish Diet, Cancer, and Health; HDL-C, high-density lipoprotein cholesterol; IQR, interquartile range; MESA, Multi-Ethnic Study of Atherosclerosis; and N/A, not available. *Carotid intimamedia thickness was available in only 5494 of the MESA participants.
†Physical activity includes moderate and vigorous activity. Participants reporting >18 h/d of total physical activity excluded (MESA, N=4894 after exclusions).
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CI, 0.95-1.25) in MESA and 1.03 (95% CI, 0.92-1.15) in DCH. The relative risks associated with HDL containing and lacking apoC-III were significantly different from each other (P for heterogeneity in multivariable-adjusted models was 0.03 in MESA and 0.01 in DCH).
Measures of apoC-III, including the absolute concentration of apoC-III within the plasma HDL fraction (only available in DCH) and total plasma apoC-III, both showed tendencies for a higher risk of CHD with higher levels, but neither of them was statistically significant in the fully adjusted models (Table 2) .
In the DCH, we obtained measures of apoC-III-defined HDL subspecies by assessing both HDL cholesterol concentrations and apoA-I concentrations. Results for HDL cholesterol containing and lacking apoC-III were similar to those reported for HDL subspecies based on apoA-I measures (Table II in the online-only Data Supplement). Cholesterol concentrations of the HDL subspecies were not measured in MESA.
Meta-Analysis of Four Studies
The divergent associations observed for HDL apoA-I containing and lacking apoC-III in MESA and DCH were similar to the results observed using HDL cholesterol measures in both DCH (Table III in the online-only Data Supplement) and the previous report from the Nurses' Health and Health Professionals Follow-Up Studies (results from all 4 cohorts shown using study-specific quintiles and SDs in Figure 1) . 18 We also repeated the analysis in each cohort using a fixed increment of 5 mg/dL for both HDL subfractions. The results, which were similar to those shown in Figure 1 , are included in Table IV in the online-only Data Supplement. Thus, we pooled all cohorts with analyses of HDL subspecies according to apoC-III and found that the multivariable-adjusted relative risk for CHD per each SD higher HDL lacking apoC-III was 0.76 (95% CI, 0.70-0.83) and the relative risk for HDL containing apoC-III was 1.09 (95% CI, 1.01-1.18) (Figure 2 and study-specific quintile medians are presented in Table V in the online-only Data Supplement and forest plots are presented in Figures I and II in the online-only Data Supplement.) Using 5 mg/dL increments, the relative risks were 0.96 (95% CI, 0.93-0.98) and 1.13 (95% CI, 0.96-1.30), respectively. The association with CHD for HDL containing apoC-III was statistically significantly different than for HDL lacking apoC-III (P for heterogeneity <0.01). Adjustment for triglycerides and LDL cholesterol attenuated the results, but HDL lacking apoC-III remained inversely associated with the risk of CHD (relative risk per Hazard ratios and 95% confidence intervals for coronary heart disease per 1 SD (in mg/dL) increments and for comparison of extreme quintiles. Multivariable model was adjusted for ASCVD risk factors: for age, sex, prevalent diabetes mellitus, treatment with antihypertensive medication, race/ethnicity (MESA), systolic blood pressure, smoking, and total cholesterol. P heterogeneity between continuous measures of apoA-I with and without apoC-III: age-and sex-adjusted model, MESA=0.01, DCH=0.0001; ASCVD factors model, MESA=0.03, DCH=0.01. Apo indicates apolipoprotein; ASCVD, atherosclerotic cardiovascular disease; DCH, Danish Diet, Cancer, and Health; HDL, high-density lipoprotein; MESA, Multi-Ethnic Study of Atherosclerosis; and NA, not available. SD, 0.84; 95% CI, 0.75-0.95), and the relative risk per each SD of HDL containing apoC-III was 1.05 (95% CI, 0.96-1.14) (P for heterogeneity =0.04).
In meta-analyses, the proportion of HDL containing apoC-III was associated with a higher risk of CHD (relative risk per SD, 1.09; 95% CI, 1.03-1.16), although each SD higher total HDL was associated with a relative risk of 0.80 (95% CI, 0.74-0.87) ( Figure III in the onlineonly Data Supplement).
Analyses in Strata of CVD Risk Factors
We analyzed the risk of CHD for each SD higher HDL containing and lacking apoC-III according to CVD risk factors in each of the 4 cohorts and pooled the data using fixed-effects meta-analysis. Shown in Figure 3 , HDL lacking apoC-III was generally inversely associated with the risk of CHD across all participant characteristics, whereas HDL containing apoC-III was associated with a higher risk of CHD. As indicated by the CIs, some subgroups had few cases (women, prevalent diabetes mellitus, use of cholesterol-lowering medication, and low HDL cholesterol level). Nevertheless, the stratified results suggested that HDL subspecies are differentially associated with CHD risk broadly across several participant characteristics associated with CHD risk. The results appeared to be slightly stronger in groups of participants characterized by lower cardiovascular per SD and using study-specific quintiles. Adjusted for atherosclerotic cardiovascular disease risk factors: age, sex, prevalent diabetes mellitus, treatment with antihypertensive medication, race/ethnicity in MESA, systolic blood pressure, smoking, and total cholesterol. Both subtypes of HDL (containing and lacking apoC-III) are simultaneously included in all models. P heterogeneity = test of the linear hypothesis that the regression coefficients for the 2 subfractions were equal (1 df Wald test). apoC indicates apolipoprotein C; CHD, coronary heart disease; CI, confidence interval; HDL, high-density lipoprotein; and RR, relative risk.
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risk, such as among those who were normal weight, nonsmokers, were free of diabetes mellitus, did not use cholesterol-lowering medication, or had HDL cholesterol >40 mg/dL, but the differences were not significant. Analyses in strata of self-reported race/ethnicity of the MESA participants only were not statistically powered to highlight the potential differences across these subgroups (Table VI in 
DISCUSSION
In this investigation of 2 large prospective studies, separation of HDL apoA-I according to the presence and absence of apoC-III identified 2 subtypes of HDL that had qualitatively different associations with the risk of CHD. In a cumulative meta-analysis of all current data on these HDL subspecies, the statistically significant direct association of HDL containing apoC-III with a risk of CHD was strikingly different from the strong, inverse association for HDL lacking apoC-III, which appeared even stronger than the association for total HDL.
Although the fraction of HDL that contains apoC-III is small (≈5% to 6% of apoA-I or 10% to 15% of HDL cholesterol has apoC-III), these investigations may shed light on ways in which the HDL proteome could result in HDL particles with more or less cardioprotective functions. Thus far, little is known about the potential effects of apoC-III on important functional aspects of HDL. We have previously demonstrated that apoC-III inhibits the clearance from the circulation of apoB-containing lipoproteins by interfering with the interaction of apoE with hepatic receptors, 12 and preliminary data from our laboratory support a similar delayed clearance of HDL containing apoC-III. We observed a weak correlation between the proportion of HDL that contains apoC-III and cholesterol efflux (0.12), consistent with their separate biological roles. As such, the measure of HDL subspecies according to apoC-III may be viewed as complementary to that of cholesterol efflux capacity via ABCA1, which is focused on the initial lipidation of the apoA-I particle but does not reflect the delivery of cholesterol to the liver. Further, apoC-III may have influence beyond cholesterol transport. Riwanto et Pooled relative risks with 95% CI for the risk of CHD estimated in fixed-effects meta-analysis using study-specific SDs and study-specific quintiles in 4 prospective studies: DCH study (Danish Diet, Cancer, and Health), MESA (Multi-Ethnic Study of Atherosclerosis), HPFS (Health Professionals Follow-Up Study), and NHS (Nurses' Health Study). Adjusted for atherosclerotic cardiovascular disease risk factors: age, sex, prevalent diabetes mellitus, treatment with antihypertensive medication, race/ ethnicity in MESA, systolic blood pressure, smoking, and total cholesterol. HDL assessed per apoA-I concentrations in MESA and DCH and per HDL cholesterol concentrations in NHS and HPFS. Both subtypes of HDL (containing and lacking apoC-III) are simultaneously included in all models. P heterogeneity = test of the linear hypothesis that the regression coefficients for the two subfractions were equal (1 df Wald test). apoC indicates apolipoprotein C; CHD, coronary heart disease; CI, confidence interval; HDL, high-density lipoprotein; and HR, hazard ratio. 30 found that compared with HDL from healthy patients, HDL from patients with CHD had elevated apoC-III levels and had lost its capacity to inhibit endothelial cell apoptosis. Earlier we found that HDL which lacks apoC-III inhibits the monocyte-endothelial cell interaction, leading to a lowered inflammatory response, whereas HDL with apoC-III did not diminish this interaction. 31 Thus, even if total HDL levels are high, this would not translate into a lower risk of CHD in individuals who have a large proportion of HDL containing apoC-III.
We also measured the total plasma concentration of apoC-III and the concentration of apoC-III in HDL in the Danish study. Consistent with the literature, we observed that although apoC-III is directly associated with CHD risk, it is not robust to adjustment for clinical risk factors and other lipids, 18, 32 suggesting that the concentrations of lipoproteins (HDL and LDL) that contain any apoC-III may be more relevant cardiovascular risk measures than total plasma apoC-III or the concentration of apoC-III in LDL and HDL. 18, 33 Strengths of this study include its large number of cases and the opportunity to look into potential effect modification by race/ethnicity and sex. However, we had limited statistical power for stratified analyses by prevalent diabetes mellitus status and use of lipid-lowering medications. In the meta-analysis, we included 2 prior publications where the surrogate measure of HDL was HDL cholesterol concentration rather than apoA-I. Hence, we used studyspecific SDs and quintiles as our primary units of measurement because no universal cut points have been identified. Similar results ensued from using fixed increments of 5 mg/dL, and overall the 2 measures of HDL-cholesterol and apoA-I-provided associations of the same magnitude and direction. The direct measure of the concentration of apoA-I containing and lacking apoC-III using 2 antibodies has shortened the process of measuring the HDL Pooled relative risks with 95% CI for the risk of CHD estimated in fixed-effects meta-analysis using study-specific SDs in 4 prospective studies: DCH study (Danish Diet, Cancer, and Health), MESA (Multi-Ethnic Study of Atherosclerosis), HPFS (Health Professionals Follow-Up Study), and NHS (Nurses' Health Study). Adjusted for atherosclerotic cardiovascular disease risk factors: age, sex, prevalent diabetes mellitus, treatment with anti-hypertensive medication, race/ethnicity in MESA, systolic blood pressure, smoking, and total cholesterol. Both subtypes of HDL (containing and lacking apoC-III) are simultaneously included in all models. apoC indicates apolipoprotein C; BMI, body mass index; CHD, coronary heart disease; CI, confidence interval; HDL, high-density lipoprotein; HDL-C, HDL cholesterol; and RR, relative risk.*Between-study heterogeneity, P<0.05. †Estimates are not available in NHS and HPFS.
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subspecies considerably and reduced measurement error, making this biomarker measure well suited for assessment in future large-scale epidemiological settings. We had information on LDL cholesterol or apoB in both MESA and DCH, but we did not measure LDL with and without apoC-III in those studies. However, we previously found in NHS and HPFS that adjustment for LDL subspecies had virtually no effect on estimates for HDL subspecies after adjustment for total LDL cholesterol. 18 Although our data suggest that apoC-III may confer proatherogenic properties to HDL, further research is necessary to establish how measures of HDL containing and lacking apoC-III relate to functional properties of HDL, such as cholesterol efflux from cells, inflammation, or cholesterol excretion.
Last, our HDL measurements from a single time point may not reflect long-term exposure and do not allow for the evaluation of associations between changes in HDL subspecies distribution with the risk of CHD.
CONCLUSIONS
In conclusion, our findings from 4 prospective studies support the hypothesis that apoC-III may mark a subfraction of HDL that is associated with a higher risk of CHD. New measures reflecting HDL structure and function may provide novel insights for cardiovascular risk that extend beyond traditional plasma HDL concentrations. 
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